SG11201406207PA - Bicyclic heterocyclic derivatives as mnk1 and mnk2 modulators and uses thereof - Google Patents

Bicyclic heterocyclic derivatives as mnk1 and mnk2 modulators and uses thereof

Info

Publication number
SG11201406207PA
SG11201406207PA SG11201406207PA SG11201406207PA SG11201406207PA SG 11201406207P A SG11201406207P A SG 11201406207PA SG 11201406207P A SG11201406207P A SG 11201406207PA SG 11201406207P A SG11201406207P A SG 11201406207PA SG 11201406207P A SG11201406207P A SG 11201406207PA
Authority
SG
Singapore
Prior art keywords
mnk2
mnk1
modulators
bicyclic heterocyclic
heterocyclic derivatives
Prior art date
Application number
SG11201406207PA
Inventor
Kassoum Nacro
Athisayamani Jeyaraj Duraiswamy
Lohitha Rao Chennamaneni
Original Assignee
Agency Science Tech & Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agency Science Tech & Res filed Critical Agency Science Tech & Res
Publication of SG11201406207PA publication Critical patent/SG11201406207PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201406207PA 2012-03-30 2013-04-01 Bicyclic heterocyclic derivatives as mnk1 and mnk2 modulators and uses thereof SG11201406207PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1205669.3A GB201205669D0 (en) 2012-03-30 2012-03-30 Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
PCT/SG2013/000126 WO2013147711A1 (en) 2012-03-30 2013-04-01 Bicyclic heterocyclic derivatives as mnk1 and mnk2 modulators and uses thereof

Publications (1)

Publication Number Publication Date
SG11201406207PA true SG11201406207PA (en) 2014-11-27

Family

ID=46160013

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201406207PA SG11201406207PA (en) 2012-03-30 2013-04-01 Bicyclic heterocyclic derivatives as mnk1 and mnk2 modulators and uses thereof
SG10201706594PA SG10201706594PA (en) 2012-03-30 2013-04-01 Bicyclic heterocyclic derivatives as mnk1 and mnk2 modulators and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201706594PA SG10201706594PA (en) 2012-03-30 2013-04-01 Bicyclic heterocyclic derivatives as mnk1 and mnk2 modulators and uses thereof

Country Status (13)

Country Link
US (3) US9908886B2 (en)
EP (2) EP2831079B1 (en)
JP (2) JP6475158B2 (en)
KR (1) KR102153320B1 (en)
CN (1) CN104350055B (en)
AU (2) AU2013240612B2 (en)
DK (1) DK2831079T3 (en)
ES (1) ES2647959T3 (en)
GB (1) GB201205669D0 (en)
NO (1) NO2831079T3 (en)
PL (1) PL2831079T3 (en)
SG (2) SG11201406207PA (en)
WO (1) WO2013147711A1 (en)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2868302A1 (en) 2012-03-23 2013-09-26 Dennis M. Brown Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo
US10280168B2 (en) 2012-03-30 2019-05-07 Agency For Science, Technology And Research Bicyclic heteroaryl derivatives as MNK1 and MNK2 modulators and uses thereof
GB201205669D0 (en) 2012-03-30 2012-05-16 Agency Science Tech & Res Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
TWI574962B (en) 2012-11-14 2017-03-21 加拓科學公司 Heteroaromatic compounds as pi3 kinase modulators and methods of use
AU2014219256B2 (en) 2013-02-21 2017-02-16 Sunshine Lake Pharma Co., Ltd. Heteroaromatic compounds as PI3 kinase modulators
US9296754B2 (en) 2013-03-15 2016-03-29 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
US9186361B2 (en) 2013-03-15 2015-11-17 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
WO2014151630A2 (en) 2013-03-15 2014-09-25 Irm Llc Compounds and compositions for the treatment of parasitic diseases
US9227969B2 (en) 2013-08-14 2016-01-05 Novartis Ag Compounds and compositions as inhibitors of MEK
AR097543A1 (en) * 2013-09-06 2016-03-23 Lexicon Pharmaceuticals Inc COMPOUNDS BASED ON IMIDAZO [1,2-b] PIRIDAZINE, COMPOSITIONS THAT INCLUDE THEM AND THEIR METHODS OF USE
TW201542550A (en) * 2013-09-06 2015-11-16 Lexicon Pharmaceuticals Inc Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them, and methods of their use
GB2518873A (en) 2013-10-03 2015-04-08 Agency Science Tech & Res Bicyclic alkyne derivatives and uses thereof
CN105814052B (en) * 2013-12-09 2018-01-12 Ucb生物制药私人有限公司 Imidazopyridine derivatives as TNF active regulators
RS58053B1 (en) 2013-12-19 2019-02-28 Novartis Ag [1,2,4]triazolo[1,5-a]pyrimidine derivatives as protozoan proteasome inhibitors for the treatment of parasitic diseases such as leishmaniasis
CA2935985A1 (en) * 2014-01-09 2015-07-16 Intra-Cellular Therapies, Inc. Organic compounds
ES2735729T3 (en) 2014-01-24 2019-12-20 Turning Point Therapeutics Inc Diaryl macrocycles as protein kinase modulators
ES2672797T3 (en) 2014-02-13 2018-06-18 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
HUE045725T2 (en) 2014-02-13 2020-01-28 Incyte Corp Cyclopropylamines as lsd1 inhibitors
ES2760261T3 (en) 2014-02-13 2020-05-13 Incyte Corp Cyclopropylamines as LSD1 inhibitors
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
TWI713455B (en) 2014-06-25 2020-12-21 美商伊凡克特治療公司 Mnk inhibitors and methods related thereto
US9695168B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,5-α]pyridines and imidazo[1,5-α]pyrazines as LSD1 inhibitors
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
US9758523B2 (en) 2014-07-10 2017-09-12 Incyte Corporation Triazolopyridines and triazolopyrazines as LSD1 inhibitors
WO2016007736A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyrazines as lsd1 inhibitors
MX2017012699A (en) 2015-04-03 2018-02-09 Incyte Corp Heterocyclic compounds as lsd1 inhibitors.
AU2016252038B2 (en) 2015-04-20 2021-08-12 Effector Therapeutics, Inc. Inhibitors of immune checkpoint modulators for use in treating cancer and infections
EP3288940B9 (en) * 2015-04-29 2021-07-21 Janssen Pharmaceutica NV Azabenzimidazoles and their use as ampa receptor modulators
JP6986972B2 (en) * 2015-06-18 2021-12-22 エイティナイン バイオ リミテッド Substituted 4-benzyl and 4-benzoylpiperidin derivatives
JP6999424B2 (en) 2015-06-18 2022-01-18 エイティナイン バイオ リミテッド 1,4-substituted piperidine derivative
US10316044B2 (en) 2015-07-02 2019-06-11 Tp Therapeutics, Inc. Chiral diaryl macrocycles as modulators of protein kinases
BR112018000297A2 (en) 2015-07-06 2018-09-04 Tp Therapeutics Inc diaryl macrocycle polymorph
BR112018001065A2 (en) 2015-07-21 2018-09-11 Tp Therapeutics, Inc. chiral diaryl macrocycles and uses thereof
KR20180051523A (en) 2015-08-12 2018-05-16 인사이트 코포레이션 Salt of LSD1 inhibitor
EP3344039A4 (en) 2015-09-03 2019-08-28 Arizona Board of Regents on behalf of the University of Arizona Small molecule inhibitors of dyrk1a and uses thereof
MX2018004879A (en) * 2015-10-22 2019-02-28 Selvita S A Pyridone derivatives and their use as kinase inhibitors.
US10851082B2 (en) 2015-10-28 2020-12-01 Northwestern University Substituted aromatic n-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (MNK1) and 2 (MNK2)
KR20180070696A (en) * 2015-10-29 2018-06-26 이펙터 테라퓨틱스, 인크. Pyrrolo-, pyrazolo-, imidazo-pyrimidine and pyridine compounds which inhibit MNK1 and MNK2
EA201891049A1 (en) 2015-10-29 2018-10-31 Эффектор Терапьютикс, Инк. ISOINDOLINE, AZAISOINDOLINE, DIHYDROINDENONE AND DIHYDROAZAINDENONE INHIBITORS MNK1 AND MNK2
US10000487B2 (en) 2015-11-20 2018-06-19 Effector Therapeutics, Inc. Heterocyclic compounds that inhibit the kinase activity of Mnk useful for treating various cancers
US20170191136A1 (en) 2015-12-31 2017-07-06 Effector Therapeutics, Inc. Mnk biomarkers and uses thereof
SG11201809299QA (en) 2016-04-22 2018-11-29 Incyte Corp Formulations of an lsd1 inhibitor
WO2018013430A2 (en) 2016-07-12 2018-01-18 Arisan Therapeutics Inc. Heterocyclic compounds for the treatment of arenavirus infection
MX2019001125A (en) 2016-07-28 2019-06-12 Tp Therapeutics Inc Macrocycle kinase inhibitors.
GB201700692D0 (en) * 2017-01-16 2017-03-01 Salvensis Novel compounds and their use in the treatment of schistosomiasis
TWI808958B (en) 2017-01-25 2023-07-21 美商特普醫葯公司 Combination therapy involving diaryl macrocyclic compounds
AU2018220840A1 (en) 2017-02-14 2019-09-19 Effector Therapeutics, Inc. Piperidine-substituted Mnk inhibitors and methods related thereto
BR112020001695A2 (en) 2017-07-28 2020-07-21 Turning Point Therapeutics, Inc. macrocyclic compounds and their uses
ES2929467T3 (en) 2017-12-19 2022-11-29 Turning Point Therapeutics Inc Macrocyclic compounds to treat diseases
CN110156786B (en) * 2018-02-13 2022-06-03 青煜医药研发(上海)有限公司 Pyrimido-cyclic compounds, process for their preparation and their use
SG11202007740TA (en) * 2018-02-13 2020-09-29 Shanghai Blueray Biopharma Co Ltd Pyrimidine-fused cyclic compound, preparation method therefor and application thereof
EP3564235A1 (en) * 2018-05-03 2019-11-06 Northwestern University Substituted aromatic n-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (mnk1) and 2 (mnk2)
WO2020047198A1 (en) 2018-08-31 2020-03-05 Incyte Corporation Salts of an lsd1 inhibitor and processes for preparing the same
CN113164476A (en) * 2018-09-28 2021-07-23 代表亚利桑那大学的亚利桑那校董会 Small molecule inhibitor of DYRK1/CLK and application thereof
MX2021004763A (en) 2018-10-24 2021-06-08 Effector Therapeutics Inc Crystalline forms of mnk inhibitors.
CN111978325B (en) * 2019-05-22 2023-11-17 中国药科大学 Imidazopyridazine MNK1/MNK2 kinase inhibitor, and preparation method and application thereof
CN111978317A (en) * 2019-05-22 2020-11-24 上海道熵生物科技有限公司 Imidazopyridine MNK1/MNK2 kinase inhibitor and preparation method and application thereof
KR102459614B1 (en) * 2019-08-30 2022-10-31 주식회사 티에스디라이프사이언스 Imidazopyridine derivatives, and pharmaceutical composition containing the same as an active ingredient
US20230093480A1 (en) * 2019-12-30 2023-03-23 Devicare SL Compositions for clinical complications associated to devices implanted in the urinary tract
US20230355617A1 (en) * 2020-09-14 2023-11-09 The University Of Sussex Small molecule inhibitors of lemur tyrosine kinase 3
CN112047950B (en) * 2020-09-14 2023-07-25 华东师范大学 Imidazo pyrazine derivative and synthetic method and application thereof
US20230000986A1 (en) * 2021-07-01 2023-01-05 Board Of Regents, The University Of Texas System Mnk inhibitors and eif4e phosphorylation modulation to treat inflammatory pain in the aged
WO2023093700A1 (en) * 2021-11-29 2023-06-01 中国海洋大学 Imidazothiazole derivative, preparation method therefor, and application thereof
CN114113639B (en) * 2022-01-29 2022-04-19 北京大有天弘科技有限公司 Blood type antibody detection method and application thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1746099A1 (en) * 2004-12-23 2007-01-24 DeveloGen Aktiengesellschaft Mnk1 or Mnk2 inhibitors
US20100216798A1 (en) * 2005-07-29 2010-08-26 Astellas Pharma Inc Fused heterocycles as lck inhibitors
US20070049591A1 (en) * 2005-08-25 2007-03-01 Kalypsys, Inc. Inhibitors of MAPK/Erk Kinase
CN101454325A (en) * 2006-03-09 2009-06-10 法马科皮亚公司 8-heteroarylpurine mnk2 inhibitors for treating metabolic disorders
CA2654358A1 (en) * 2006-06-22 2007-12-27 Biovitrum Ab (Publ) Pyridine and pyrazine derivatives as mnk kinase inhibitors
US20120058997A1 (en) * 2006-11-06 2012-03-08 Supergen, Inc. Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
BRPI0718029A2 (en) * 2006-11-06 2013-11-26 Supergen Inc IMIDAZO (1,2-B) PYRIDAZINE AND PIRAZOLE (1,5-A) PYRIMIDINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS
AR064491A1 (en) * 2006-12-22 2009-04-08 Astex Therapeutics Ltd IMIDAZO DERIVATIVES [1, 2-A] PYRIMIDINE, A PROCESS FOR PREPARATION, A PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM AND ITS USE IN THE TREATMENT OF DISEASES MEDIATED BY FGFR KINASES.
AR067326A1 (en) * 2007-05-11 2009-10-07 Novartis Ag IMIDAZOPIRIDINES AND PIRROLO -PIRIMIDINES REPLACED AS INHIBITORS OF LIPIDO KINASE
PE20091383A1 (en) * 2007-10-17 2009-10-17 Novartis Ag DERIVATIVES OF IMIDAZO- [1,2-a] PYRIDINE AS INHIBITORS OF ALK-5 AND ALK-4
US20110280886A1 (en) * 2008-11-12 2011-11-17 University Hospital Basel Treating cancer by modulating mnk
TW201107329A (en) * 2009-07-30 2011-03-01 Oncotherapy Science Inc Fused imidazole derivative having ttk inhibitory action
CN105078978A (en) * 2009-08-17 2015-11-25 因特利凯公司 Heterocyclic compounds and uses thereof
UY33241A (en) 2010-02-26 2011-09-30 Boehringer Ingelheim Int ? Tienopyrimidines containing heterocycloalkyl for pharmaceutical compositions ?.
TW201144310A (en) * 2010-04-28 2011-12-16 Daiichi Sankyo Co Ltd [5,6] heterocyclic compound
JP5926727B2 (en) * 2010-07-28 2016-05-25 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ Substituted imidazo [1,2-b] pyridazine
GB201205669D0 (en) * 2012-03-30 2012-05-16 Agency Science Tech & Res Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
US10280168B2 (en) 2012-03-30 2019-05-07 Agency For Science, Technology And Research Bicyclic heteroaryl derivatives as MNK1 and MNK2 modulators and uses thereof
WO2014138692A1 (en) * 2013-03-07 2014-09-12 Califia Bio, Inc. Mixed lineage kinase inhibitors and method of treatments

Also Published As

Publication number Publication date
DK2831079T3 (en) 2017-11-27
SG10201706594PA (en) 2017-09-28
PL2831079T3 (en) 2018-01-31
US20180208600A1 (en) 2018-07-26
JP2019031560A (en) 2019-02-28
KR102153320B1 (en) 2020-09-08
EP2831079B1 (en) 2017-08-16
AU2017219039A1 (en) 2017-09-14
ES2647959T3 (en) 2017-12-27
JP2015511638A (en) 2015-04-20
CN104350055A (en) 2015-02-11
JP6475158B2 (en) 2019-02-27
WO2013147711A1 (en) 2013-10-03
EP3321268A1 (en) 2018-05-16
US20190315755A1 (en) 2019-10-17
AU2013240612B2 (en) 2017-05-25
KR20150002639A (en) 2015-01-07
EP2831079A4 (en) 2015-11-18
NO2831079T3 (en) 2018-01-13
AU2013240612A1 (en) 2014-10-16
JP6662984B2 (en) 2020-03-11
CN104350055B (en) 2019-05-31
EP2831079A1 (en) 2015-02-04
US11040978B2 (en) 2021-06-22
GB201205669D0 (en) 2012-05-16
US20140371199A1 (en) 2014-12-18
US9908886B2 (en) 2018-03-06

Similar Documents

Publication Publication Date Title
SG10201706594PA (en) Bicyclic heterocyclic derivatives as mnk1 and mnk2 modulators and uses thereof
HRP20181310T1 (en) Novel heterocyclic derivatives and their uses
HK1207069A1 (en) Heterocyclic compounds and uses thereof
EP2828258A4 (en) Novelpyridopyrimidine derivatives and use thereof
HK1201521A1 (en) Heterocyclic compounds and methods for their use
SG11201503535PA (en) Hollow hydrogel capsules and methods of using the same
HK1201533A1 (en) Heterocyclic compounds and methods for their use
HK1201531A1 (en) Heterocyclic compounds and methods for their use
AP3611A (en) Heterocyclic compounds and their uses
HK1198833A1 (en) N-acylpeptide derivatives and their uses n-
HK1198949A1 (en) Absorber and absorbent article using the same
EP2909181A4 (en) Pkm2 modulators and methods for their use
IL252033B (en) Spiro derivatives and processes for the preparation thereof
HK1204327A1 (en) Aurora and flt3 kinases modulators flt3
GB2500340B (en) Carrying aid especially for use with children
EP2870133A4 (en) Tetrahydro-isohumulone derivatives, methods of making and using
GB201212570D0 (en) Carrying aid especially for use with children